A novel paradigm for immunity and vaccine development against group A streptococcus

针对 A 组链球菌的免疫和疫苗开发的新范例

• 批准号: nhmrc : 1064408
• 负责人: Dr Joseph Kado
• 金额: $ 32.76万
• 依托单位: Murdoch Childrens Research Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-paradigm-immunity-group-streptococcus/455118
• 关键词: novel; paradigm; immunity; vaccine; development

Serious disease caused by the group A streptococcus (GAS) is responsible for more than 500,000 deaths per year. With no effective control strategies available, a vaccine is urgently needed. One vaccine shows great promise, but there are concerns it may not cover all GAS strains. Our project aims to show that the vaccine may in fact have very broad coverage because of cross-protection between strains using natural immunity model, and may lead to a new paradigm in understanding of GAS immunity.

由 A 族链球菌 (GAS) 引起的严重疾病每年导致超过 500,000 人死亡。由于没有有效的控制策略，迫切需要疫苗。一种疫苗显示出巨大的希望，但有人担心它可能无法覆盖所有 GAS 毒株。我们的项目旨在表明，由于使用自然免疫模型的毒株之间的交叉保护，该疫苗实际上可能具有非常广泛的覆盖范围，并可能导致理解 GAS 免疫的新范式。